The Oklahoma Rheumatic Disease Research Core Center in Human Genetics (ORDRCCHG) will build on the strengths of the Oklahoma Medical Research Foundation Arthritis and Immunology program and expand this leadership to apply cutting edge genetic approaches to complex rheumatic disease problems. By melding human geneticists, developmental immunologists, immunogeneticists, theoretical physicists, molecular biologists, and inflammation experts with pediatric and adult clinical investigators (spanning the clinical disciplines of rheumatology, dermatology, hematology/oncology, endocrinology, allergy/immunology, genetics and cardiology), this core center will enhance a multidisciplinary approach to rheumatic disease research. The emphasis of this Core Center will apply the resources and infrastructure being developed in human genetics for systemic rheumatic diseases. Now that substantial progress has been made in the identification of key genetic susceptibility regions in SLE, this core center will provide key support to entice outside investigators into the characterization of the key genes located within these regions. In addition, parallel, but experience refined, approaches can be applied to other systemic autoimmune rheumatic diseases, such as scleroderma, Wegener's granulomatosis, anti-phospholipid syndrome, thrombotic thrombocytopenic purpura (TTP) and others. These efforts will be enhanced by the key scientific cores for 1) High throughput SNP genotyping, association testing, and expression, 2) Data analysis and 3) Sample procurement and management. Coordinated efforts by the Administrative Core will also streamline regulatory requirements through support for human subjects training, IRB applications, HIPPA compliance, grants management, publication support and data management will greatly enhance research efforts, especially for junior investigators or basic scientists branching into rheumatic disease research. A comprehensive and multidisciplinary Enhancement Program will provide ongoing multidisciplinary training through seminars, visiting professorships, workshops and mentoring program will enhance the research and educational environment in Oklahoma. The long-term goals of the ORDRCCHG are to provide key insights to the etiology and pathogenesis of autoimmune systemic rheumatic diseases through implementation of a multidisciplinary approach among a cadre of internationally recognized investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053483-04
Application #
7938658
Study Section
Special Emphasis Panel (ZAR1-KM-K (M1))
Program Officer
Witter, James
Project Start
2007-09-01
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
4
Fiscal Year
2010
Total Cost
$560,720
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247
Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531
Jog, Neelakshi R; Chakravarty, Eliza F; Guthridge, Joel M et al. (2018) Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Front Immunol 9:2198
Hanscombe, Ken B; Morris, David L; Noble, Janelle A et al. (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27:3813-3824
Bagavant, Harini; Dunkleberger, Micah L; Wolska, Nina et al. (2018) Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol :
Scofield, R Hal; Sharma, Rohan; Harris, Valerie M (2018) Reply. Arthritis Rheumatol 70:626-627
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2018) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:298-307
St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480
Martínez-Bueno, Manuel; Oparina, Nina; Dozmorov, Mikhail G et al. (2018) Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. Int J Mol Sci 19:
Koelsch, Kristi A; Cavett, Joshua; Smith, Kenneth et al. (2018) Evidence of Alternative Modes of B Cell Activation Involving Acquired Fab Regions of N-Glycosylation in Antibody-Secreting Cells Infiltrating the Labial Salivary Glands of Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:1102-1113

Showing the most recent 10 out of 284 publications